NCT05757843 is a Phase 2 clinical trial of Signatera ctDNA test in NSCLC, Stage III, sponsored by Indiana University.

Who is sponsoring NCT05757843?

NCT05757843 is sponsored by Indiana University.

What drugs are being tested in NCT05757843?

Interventions in NCT05757843: Signatera ctDNA test, Durvalumab.

What condition does NCT05757843 study?

NCT05757843 studies NSCLC, Stage III.

Is NCT05757843 still recruiting?

NCT05757843 is currently withdrawn. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05757843

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Withdrawn Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing Signatera ctDNA test in NSCLC, Stage III. Withdrawn.

Timeline

13 September 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Indiana University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	13 September 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025

Drugs / interventions tested

Signatera ctDNA test
Durvalumab — full drug profile →

Conditions studied

NSCLC, Stage III — all drugs for NSCLC, Stage III →

Sponsor

Indiana University

Who can join

18 and older, any sex, with NSCLC, Stage III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Decoding the Dynamics of Circulating Tumor DNA in Liquid Biopsies.
Turabi K, Klute K, Radhakrishnan P. · · 2024 · cited 14× · PMID 39001494 · DOI 10.3390/cancers16132432
Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y, Yoon SM, Lee J, Park JH, et al · · 2024 · cited 13× · PMID 38558374 · DOI 10.1111/1759-7714.15281

Verify or expand the search:

Other recruiting trials for NSCLC, Stage III

Currently open trials in the same condition.

NCT06467383 — A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced · recruiting
NCT05344209 — Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT04585490 — Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in S · Phase 3 · recruiting
NCT04392505 — Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study · Phase 2 · active not recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05757843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05757843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing